Pfizer, in collaboration with the Hemostasis and Thrombosis Research Society (HTRS), is offering a new Independent Medical Education (IME) grant opportunity under the 2025 RD US HTRS Hemophilia Visiting Professorship program. This initiative aims to support U.S.-based academic institutions and healthcare organizations that have limited resources or experience with hemophilia-specific medical education. Selected applicants will host a two-day medical education program led by an HTRS-selected Visiting Professor with expertise in hemophilia, specifically in the area of shared decision making (SDM) and emerging therapeutic options.
The Visiting Professorship is designed to enhance physician and healthcare team education surrounding hemophilia treatment and patient engagement strategies. Educational content must address unmet medical gaps, challenges, or questions related to SDM and novel therapies. Each hosting organization will work closely with HTRS to customize the program to meet local educational needs. The Visiting Professor’s travel expenses and honoraria are not part of the grant budget, as they will be handled directly by HTRS.
Eligible applicants include professional medical, pharmacy, nursing, allied health, dental schools, universities, academic health centers, and nonprofit professional associations. Applicants must be legally able to accept funding from Pfizer, and if continuing education (CE) credit is offered, accreditation must be documented. The grant will provide up to $7,500 USD per site to cover local program costs such as room rental, AV support, planning, and staffing.
The RFP was released on September 17, 2025. Completed proposals must be submitted by October 28, 2025, at 5:00 PM ET. Pfizer and HTRS will notify selected recipients by November 21, 2025, with programs expected to start after January 2, 2026. Approximately eight sites will be supported. Required submission components include a project agenda, identified educational needs, expected outcomes, budget, and organizational letter of support. Applications must be submitted through Pfizer’s CyberGrants portal, selecting “Genetics - Hemophilia” as the primary area of interest.
Questions about this RFP should be directed to Talita Honorato-Rzeszewicz at Pfizer (talita.honorato-rzeszewicz@pfizer.com) or Danielle Horwitz at HTRS (dhorwitz@htrs.org).
Ensure application is complete and uses correct CyberGrants portal. Select “Genetics - Hemophilia” and “2025 RD US HTRS Hemophilia Visiting Professorship IME” as identifiers.
